Post-Renal Transplant Care in a 15-Year-Old

1. Immunosuppression - The Core of Post-Transplant Care

Standard Regimen

• Brenner and Rector's The Kidney, p. 2015

Tacrolimus Monitoring

• Initial target trough levels: 10-15 ng/mL
• After 6 months: gradually taper to 3-6 ng/mL (center-specific protocols)
• Tacrolimus metabolism varies significantly; younger children may need higher weight-based doses
• CYP3A5 allele variants account for >50% of inter-individual variability in tacrolimus levels
• Check levels 3x per week in the immediate post-transplant period; recalibrate whenever drugs with CYP3A4 interactions are added (e.g. macrolides, azole antifungals)
• Grapefruit/grapefruit juice inhibits enteric CYP3A4 - must be avoided
• Brenner and Rector's The Kidney, p. 2018

Cyclosporine (if used instead of tacrolimus)

• Trough levels 150-300 mcg/L initially; 75-125 mcg/L after first 6 months
• Cosmetic side effects (hirsutism, gum hyperplasia, coarse facies) are a major adherence problem in teenagers - assess at every visit
• Brenner and Rector's The Kidney, p. 2017

Mycophenolate / Azathioprine

• Monitoring of MPA trough (C0) levels is of uncertain utility but some centers use it
• Dose adjustments based on side effects (GI toxicity, cytopenias) are common

2. Monitoring Graft Function

• Acute T-cell mediated rejection (TCMR)
• Antibody-mediated rejection (AMR) - more resistant to treatment
• CNI nephrotoxicity
• BK virus nephropathy
• Urinary tract obstruction or infection

• Campbell-Walsh-Wein Urology, p. 268

3. Infection Prophylaxis and Monitoring

• Brenner and Rector's The Kidney, Table 70.17

Prophylaxis Protocol

• Trimethoprim-sulfamethoxazole (TMP-SMX): 6-12 months post-transplant for PCP (Pneumocystis jirovecii)
• Antiviral (valganciclovir/ganciclovir): 3-6 months for CMV prophylaxis, especially in CMV donor+/recipient- (highest risk) scenarios
• If a substantial increase in immunosuppression is given (e.g. for rejection), restart both TMP-SMX and antiviral prophylaxis
• Brenner and Rector's The Kidney, p. 3006

BK Virus

• Screen with plasma BK PCR every 1-3 months in the first 2 years
• BK nephropathy (BKVAN) is managed by reducing immunosuppression - no approved antivirals

CMV

• Serial CMV PCR monitoring; pre-emptive treatment if viremia rises

EBV / PTLD

• At age 15, many patients may be EBV seronegative (especially if transplanted young)
• EBV-seronegative recipients receiving EBV-seropositive grafts are at highest PTLD risk
• Monitor EBV viral load; reduce immunosuppression if rising; consider rituximab in established PTLD
• Sleisenger and Fordtran's GI and Liver Disease, p. 1108

4. Vaccination

• Influenza (inactivated) - annually
• PCV13 (pneumococcal conjugate)
• PPSV23 - every 5 years
• Tdap/Td booster every 10 years
• HPV vaccine (9vHPV) - only up to age 26 years (a 15-year-old should receive this)
• HepB series if anti-HBs <10 mIU/mL
• MenACWY, MenB, Hib

• Brenner and Rector's The Kidney, Table 70.19

5. Cardiovascular and Metabolic Complications

• Hypertension: Very common post-transplant (due to CNI effect, steroids, graft dysfunction). Target BP <75th percentile for age/height. First-line: CCBs or ACE inhibitors/ARBs
• Post-transplant diabetes mellitus (PTDM): Due to tacrolimus + steroid effect; screen fasting glucose/HbA1c regularly
• Dyslipidemia: Ciclosporin causes more dyslipidemia than tacrolimus; manage with statins if needed (check for drug interactions with CNIs)
• Obesity and weight gain: Steroid-related; dietary counselling important
• Bone disease: Steroid-induced osteopenia; calcium and vitamin D supplementation; consider DXA scans

6. Malignancy Surveillance

• PTLD (post-transplant lymphoproliferative disorder) - highest risk in EBV-naïve recipients; peak in first 2 years
• Skin cancers - annual dermatologic screening; sun protection counselling
• Cervical cancer - HPV-related; ensure HPV vaccination, and initiate cervical smear screening per age guidelines
• Cancer screening per general population guidelines (colonoscopy when indicated, etc.)
• Brenner and Rector's The Kidney, p. 3005

7. Adolescent-Specific Issues (Critical at Age 15)

Medication Non-Adherence - The Biggest Threat

• Non-adherence is the strongest predictor of allograft failure in adolescents
• Allograft loss is 7 times higher in non-adherent patients
• Causes: denial, peer pressure, body image concerns (cosmetic CNI side effects), school schedules, desire for independence
• Brenner and Rector's The Kidney, p. 2000

• Simplify regimen (once-daily extended-release tacrolimus where possible)
• Use pill boxes, smartphone reminder apps
• Measure within-patient variability of CNI levels as a non-adherence marker
• Monitor for sub-therapeutic drug levels and "Did Not Attend" rates
• Involve the patient - not just the parents - in all decisions about their care
• Belatacept (IV every 4 weeks) may be useful in highly non-adherent teenagers, though PTLD risk needs consideration
• Renal Association Clinical Practice Guideline on Post-Operative Kidney Transplant Care

Growth and Puberty

• Steroids suppress linear growth - steroid-free or steroid-minimization protocols are preferred in pediatric recipients
• Monitor height, weight, bone age at regular intervals
• Recombinant growth hormone can be considered in short-stature patients post-transplant
• Puberty may be delayed in CKD; monitor Tanner staging; endocrine referral if delayed

Transition Planning

• Begin transition to adult nephrology services from around age 14-16
• Poor transition management is a recognized cause of graft loss in late adolescence/early adulthood
• Structured transition programs with overlap of pediatric and adult care

Psychosocial and Educational Support

• School reintegration after transplant
• Screen for depression and anxiety - common in adolescent transplant recipients
• Address body image (especially with steroid weight gain, hirsutism on cyclosporine)
• Sexual health education, contraception counselling (teratogenicity of MMF - avoid in pregnancy)

8. Dietary and Lifestyle Guidance

• Low sodium diet (especially for hypertension)
• Avoid grapefruit and St. John's Wort (both affect CNI levels)
• Adequate calcium and vitamin D intake
• Limit potassium if hyperkalaemia (CNI-related)
• Exercise encouraged; avoid contact sports if graft is superficial
• Sun protection (broad-spectrum sunscreen; protective clothing) - lifelong, given skin cancer risk

Summary of Key Priorities at 15 Years

Immediate Post-Operative Care - Day 0 (Today)

1. SETTING - Where Should the Patient Be?

• Paediatric Intensive Care Unit (PICU) for at least 24 hours - mandatory
• Extubation at the end of surgery if the operation was smooth; post-op ventilation may be needed for a few hours if there was a high fluid load intraoperatively
• Continuous monitoring: heart rate, SpO2, invasive or non-invasive blood pressure, CVP, hourly urine output via suprapubic/urethral catheter
• • Management of the Paediatric Kidney Transplant Recipient, heiBOOKS 2026

2. FLUID MANAGEMENT - The Top Priority

Why it matters

Target parameters (first 24 hours)

Fluid regimen

• Insensible losses: 400-500 mL/m²/day using a dextrose-containing crystalloid
• Urine replacement (ml-for-ml): Replace urine output hourly with 0.45% or 0.9% normal saline
• The first 24-48 hours often brings a polyuric phase - a well-functioning graft with an adult kidney initially lacks urinary concentrating ability; hourly urine output can approach the patient's entire blood volume. This is expected and good, but requires meticulous hourly replacement to avoid volume depletion
• After 48 hours polyuria subsides as the kidney adapts to the child's circulation
• Initial fluid rate: 4-6 mL/kg/hour Sterofundin ISO (or equivalent balanced isotonic crystalloid), then adjust to diuresis
• If CVP or MAP falls despite fluids, consider catecholamines (norepinephrine or dopamine) - but only after confirming adequate volume status first
• No diuretics, no dopamine empirically, no mannitol unless specifically indicated

3. MONITORING - Hourly/Frequent Checks

Vitals

• Hourly vital signs (HR, BP, RR, temperature, SpO2) for first 24 hours
• Then every 2 hours for 8 hours in stable patients, then every 4 hours

Urine output

• Strict UO measurement every 30-60 minutes in the first 24 hours
• Sudden anuria or oliguria = emergency - see complications below

Lab monitoring

Imaging

• Renal Doppler ultrasound within 30 minutes of PICU arrival - to confirm vascular flow in the graft and detect early thrombosis
• Repeat Doppler ultrasound within 24 hours (routine)
• MAG3 renal scan (or DTPA) at Day 2-3 to confirm perfusion across the whole kidney

4. EARLY SURGICAL COMPLICATIONS TO WATCH FOR

Vascular Thrombosis (Most feared)

• Renal artery thrombosis (<1%): Sudden complete anuria in a previously well-perfusing graft; urgent Doppler immediately; if confirmed → emergency re-exploration - chance of saving kidney is low unless found within minutes
• Renal vein thrombosis (1-6%): More common; peak at Day 3-9; presents as sudden loss of UO with blood-stained urine, severe graft pain, possible leg swelling; urgent Doppler; emergency surgical re-exploration
• Risk is higher in the presence of hypotension, volume depletion, or prothrombotic states
• Comprehensive Clinical Nephrology 7th ed., p. 1403

Haemorrhage

• Unsecured hilar vessels can begin bleeding post-operatively
• Monitor drain output, Hb, Hct every 12 hours
• Graft pain + haemodynamic instability + falling Hb = emergency re-exploration
• Anastomotic haemorrhage is rare but presents with circulatory collapse - immediate return to OR

Urinary Complications

• Urine leak (from ureteric anastomosis): presents in first few days with rising creatinine despite some UO, pain, and wound swelling
• Ureteric obstruction: rising creatinine, reduced UO - urgent ultrasound
• Ensure catheter patency at all times (a blocked catheter mimics graft non-function)
• Check catheter flushing if UO drops suddenly - rule out catheter block before assuming graft problem

Delayed Graft Function (DGF)

• Graft produces little/no urine immediately post-op (especially with deceased donor organs)
• Requires dialysis support post-transplant
• Does NOT mean the graft has failed - continue immunosuppression
• Distinguish from primary non-function and acute rejection with biopsy if needed

5. ANTICOAGULATION PROPHYLAXIS

• Management of the Paediatric Kidney Transplant Recipient, heiBOOKS 2026

6. IMMUNOSUPPRESSION - Starting Today

• Induction agent (given in OR or immediately post-op): Basiliximab (IL-2R antagonist) or anti-thymocyte globulin (ATG) - depending on immunological risk
• Tacrolimus: Start on Day 0 or Day 1; check trough daily from 3rd dose; target 10-15 ng/mL initially
• Mycophenolate mofetil (MMF): Start perioperatively
• Methylprednisolone IV: High-dose bolus intraoperatively, then taper to oral prednisolone
• No NSAIDs at any point - risk of AKI and anastomotic complications
• Avoid morphine (accumulating metabolites can cause AKI) - use paracetamol + hydromorphone (PCA if appropriate)

7. BLOOD PRESSURE MANAGEMENT

• Hypotension: Treat aggressively with fluids first; if persists, use vasopressors (norepinephrine preferred) - essential for graft perfusion
• Hypertension: Very common due to volume loading, steroids, CNIs
  • Moderate hypertension is tolerated in the first 24-48 hours (the adult graft needs time to adjust to lower child-sized perfusion pressure)
  • Severe hypertension (>95th percentile persisting after Day 2, or symptomatic): Start amlodipine (long-acting CCB - safe choice)
  • Avoid rapid-acting nifedipine (unsafe BP drop risk)
  • Avoid ACE inhibitors/ARBs in the early post-transplant period (can impair graft perfusion in a newly revascularised kidney)
• St John's Hospital Post-Operative Challenges in Pediatric Renal Transplant

8. PAIN MANAGEMENT

• Paracetamol (scheduled) + hydromorphone PCA
• No NSAIDs - nephrotoxic and impair anastomotic healing
• Avoid morphine - accumulating metabolites (morphine-6-glucuronide) can worsen renal function

9. ANTIBIOTICS AND INFECTION

• Perioperative antibiotic prophylaxis: typically cephalosporin (dose adjusted per body surface area)
• Start TMP-SMX (Pneumocystis prophylaxis) as soon as tolerated orally
• Start valganciclovir (CMV prophylaxis) once oral intake established - especially important if CMV D+/R- or D+/R+
• Begin antifungal prophylaxis per center protocol (fluconazole in most)

10. OTHER IMMEDIATE STEPS

• Incentive spirometry / breathing exercises every 1-2 hours to prevent atelectasis
• Early mobilization by post-op Day 1 (if stable)
• Clear liquids on the night of surgery if patient is awake and extubated; advance diet as tolerated
• Isolation precautions: patient wears a mask when leaving room; limit visitors to 2
• No foley catheter removal until surgical team clears it (bladder rest protects ureteric anastomosis - usually 5-7 days)

Red Flags - Call the Surgical Team Immediately If:

Bottom line for a 15-year-old on Day 0: The kidney is an adult-sized organ in a teenager's body - haemodynamics are the priority. Maintain MAP >80 mmHg and CVP 7-10 mmHg, replace urine output ml-for-ml, get Doppler within 30 minutes, watch for sudden anuria (thrombosis), and ensure tacrolimus is on board with early trough monitoring.